Clinical trial
Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic…
NCT00270049 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00270049 |
|---|---|
| Title | Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia |
| Official title | The Effect of Subcutaneous r-HuEPO in Patients With Chronic Lymphocytic Leukemia |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Leukemia, Lymphocytic, Chronic, Cancer, Neoplasms, Quality of Life |
| Intervention type | Drug |
| Interventions | epoetin alfa |
| Enrollment | 195 |
| Start date | Nov 1, 1990 |
| Completion | Jan 1, 1994 |
| First posted | Dec 26, 2005 |
| Last update posted | May 18, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: